ID   HRH3_RAT                Reviewed;         445 AA.
AC   Q9QYN8; Q9QYN6; Q9QYN7; Q9QYN9;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   24-JUL-2024, entry version 149.
DE   RecName: Full=Histamine H3 receptor;
DE            Short=H3R;
DE            Short=HH3R;
GN   Name=Hrh3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hypothalamus;
RX   PubMed=10869375;
RA   Lovenberg T.W., Pyati J., Chang H., Wilson S.J., Erlander M.G.;
RT   "Cloning of rat histamine H3 receptor reveals distinct species
RT   pharmacological profiles.";
RL   J. Pharmacol. Exp. Ther. 293:771-778(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Corpus striatum;
RX   PubMed=11130725; DOI=10.1038/35048583;
RA   Morisset S., Rouleau A., Ligneau X., Gbahou F., Tardivel-Lacombe J.,
RA   Stark H., Schunack W., Ganellin C.R., Schwartz J.-C., Arrang J.-M.;
RT   "High constitutive activity of native H3 receptors regulates histamine
RT   neurons in brain.";
RL   Nature 408:860-864(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4).
RA   Itadani H., Takimura T., Nakamura T., Ohta M.;
RT   "Cloning of a novel G protein-coupled receptor.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=10347254; DOI=10.1124/mol.55.6.1101;
RA   Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A.,
RA   Jackson M.R., Erlander M.G.;
RT   "Cloning and functional expression of the human histamine H3 receptor.";
RL   Mol. Pharmacol. 55:1101-1107(1999).
CC   -!- FUNCTION: The H3 subclass of histamine receptors could mediate the
CC       histamine signals in CNS and peripheral nervous system. Signals through
CC       the inhibition of adenylate cyclase and displays high constitutive
CC       activity (spontaneous activity in the absence of agonist).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=H3L;
CC         IsoId=Q9QYN8-1; Sequence=Displayed;
CC       Name=2; Synonyms=H3S;
CC         IsoId=Q9QYN8-2; Sequence=VSP_001887;
CC       Name=3;
CC         IsoId=Q9QYN8-3; Sequence=VSP_001888;
CC       Name=4;
CC         IsoId=Q9QYN8-4; Sequence=VSP_001888, VSP_001889;
CC   -!- TISSUE SPECIFICITY: Expressed abundantly in brain, most notably
CC       throughout the thalamus, the ventromedial hypothalamus and the caudate
CC       nucleus. Isoform 1 is largely predominant in all tissues.
CC       {ECO:0000269|PubMed:10347254}.
CC   -!- MISCELLANEOUS: Proxyfan acts as a potent neutral antagonist while
CC       thioperamide, ciproxifan and FUB465 act as potent inverse agonists.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF237919; AAF82086.1; -; mRNA.
DR   EMBL; AY009370; AAK02069.1; -; mRNA.
DR   EMBL; AB015646; BAA88765.1; -; mRNA.
DR   EMBL; AB015646; BAA88766.1; -; mRNA.
DR   EMBL; AB015646; BAA88767.1; -; mRNA.
DR   EMBL; AB015646; BAA88768.1; -; mRNA.
DR   RefSeq; NP_001257493.1; NM_001270564.1. [Q9QYN8-2]
DR   RefSeq; NP_001257494.1; NM_001270565.1. [Q9QYN8-3]
DR   RefSeq; NP_001257497.1; NM_001270568.1. [Q9QYN8-4]
DR   RefSeq; NP_445958.1; NM_053506.2. [Q9QYN8-1]
DR   AlphaFoldDB; Q9QYN8; -.
DR   SMR; Q9QYN8; -.
DR   BioGRID; 250072; 1.
DR   STRING; 10116.ENSRNOP00000069003; -.
DR   BindingDB; Q9QYN8; -.
DR   ChEMBL; CHEMBL4124; -.
DR   DrugCentral; Q9QYN8; -.
DR   GuidetoPHARMACOLOGY; 264; -.
DR   GlyCosmos; Q9QYN8; 1 site, No reported glycans.
DR   GlyGen; Q9QYN8; 1 site.
DR   PhosphoSitePlus; Q9QYN8; -.
DR   Ensembl; ENSRNOT00000086761.2; ENSRNOP00000069003.2; ENSRNOG00000061153.2. [Q9QYN8-1]
DR   Ensembl; ENSRNOT00000116829.1; ENSRNOP00000090011.1; ENSRNOG00000061153.2. [Q9QYN8-2]
DR   Ensembl; ENSRNOT00055001632; ENSRNOP00055001306; ENSRNOG00055000969. [Q9QYN8-1]
DR   Ensembl; ENSRNOT00060001623; ENSRNOP00060000850; ENSRNOG00060001152. [Q9QYN8-1]
DR   Ensembl; ENSRNOT00065023648; ENSRNOP00065018402; ENSRNOG00065014335. [Q9QYN8-1]
DR   GeneID; 85268; -.
DR   KEGG; rno:85268; -.
DR   AGR; RGD:620630; -.
DR   CTD; 11255; -.
DR   RGD; 620630; Hrh3.
DR   GeneTree; ENSGT00940000161502; -.
DR   InParanoid; Q9QYN8; -.
DR   OMA; DIFHEVH; -.
DR   OrthoDB; 5405331at2759; -.
DR   PhylomeDB; Q9QYN8; -.
DR   Reactome; R-RNO-390650; Histamine receptors.
DR   PRO; PR:Q9QYN8; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0043176; F:amine binding; IPI:RGD.
DR   GO; GO:0016907; F:G protein-coupled acetylcholine receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:1901363; F:heterocyclic compound binding; IPI:RGD.
DR   GO; GO:0004969; F:histamine receptor activity; IEA:InterPro.
DR   GO; GO:0097159; F:organic cyclic compound binding; IMP:RGD.
DR   GO; GO:0007197; P:adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0046058; P:cAMP metabolic process; IDA:RGD.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0050890; P:cognition; IMP:RGD.
DR   GO; GO:0042756; P:drinking behavior; IMP:RGD.
DR   GO; GO:0042755; P:eating behavior; IMP:RGD.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0007612; P:learning; IMP:RGD.
DR   GO; GO:0007613; P:memory; IMP:RGD.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IMP:RGD.
DR   GO; GO:0014053; P:negative regulation of gamma-aminobutyric acid secretion; IMP:RGD.
DR   GO; GO:0014050; P:negative regulation of glutamate secretion; IMP:RGD.
DR   GO; GO:0014063; P:negative regulation of serotonin secretion; IMP:RGD.
DR   GO; GO:0090238; P:positive regulation of arachidonic acid secretion; IDA:RGD.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:RGD.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:RGD.
DR   GO; GO:0014061; P:regulation of norepinephrine secretion; IMP:RGD.
DR   GO; GO:1904321; P:response to forskolin; IDA:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IMP:RGD.
DR   CDD; cd15296; 7tmA_Histamine_H3R; 1.
DR   Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1.
DR   InterPro; IPR041998; 7tmA_HRH3.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR003980; Histamine_H3_rcpt.
DR   PANTHER; PTHR24247; 5-HYDROXYTRYPTAMINE RECEPTOR; 1.
DR   PANTHER; PTHR24247:SF194; HISTAMINE H3 RECEPTOR; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01471; HISTAMINEH3R.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..445
FT                   /note="Histamine H3 receptor"
FT                   /id="PRO_0000069692"
FT   TOPO_DOM        1..39
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        40..60
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        61..70
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        71..91
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        92..108
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        109..129
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        130..156
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        157..177
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        178..196
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        197..217
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        218..359
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        360..380
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        381..396
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        397..417
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        418..445
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          234..259
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          286..336
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        242..259
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        299..314
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P58406"
FT   CARBOHYD        11
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        107..188
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         274..321
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_001888"
FT   VAR_SEQ         274..305
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11130725, ECO:0000303|Ref.3"
FT                   /id="VSP_001887"
FT   VAR_SEQ         393..445
FT                   /note="WYETSFWLLWANSAVNPVLYPLCHYSFRRAFTKLLCPQKLKVQPHGSLEQCW
FT                   K -> CVERLGKLEASLLLPLWMFSGRWRRRKHVCELDVPWMFNQERQNCRGARGWIGR
FT                   CGLPRPPPSVLQLPAEPRQLLLPAPPPGLGRWPCPACPVCTIRIWGWVVMG (in
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_001889"
SQ   SEQUENCE   445 AA;  48588 MW;  63DFEFC21758FE5B CRC64;
     MERAPPDGLM NASGTLAGEA AAAGGARGFS AAWTAVLAAL MALLIVATVL GNALVMLAFV
     ADSSLRTQNN FFLLNLAISD FLVGAFCIPL YVPYVLTGRW TFGRGLCKLW LVVDYLLCAS
     SVFNIVLISY DRFLSVTRAV SYRAQQGDTR RAVRKMALVW VLAFLLYGPA ILSWEYLSGG
     SSIPEGHCYA EFFYNWYFLI TASTLEFFTP FLSVTFFNLS IYLNIQRRTR LRLDGGREAG
     PEPPPDAQPS PPPAPPSCWG CWPKGHGEAM PLHRYGVGEA GPGVEAGEAA LGGGSGGGAA
     ASPTSSSGSS SRGTERPRSL KRGSKPSASS ASLEKRMKMV SQSITQRFRL SRDKKVAKSL
     AIIVSIFGLC WAPYTLLMII RAACHGRCIP DYWYETSFWL LWANSAVNPV LYPLCHYSFR
     RAFTKLLCPQ KLKVQPHGSL EQCWK
//
